Condition
Keratoacanthoma
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Injection Of Tvec Into Target Lesions 3wks After 1st Injection
Related Conditions
Often studied with 19 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 4 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Injection Of Tvec Into Target Lesions 3wks After 1st Injection1
- Injection Of Tvec Into Target Lesions 2wks After 3rd Injection1
- Injection Of Tvec Into Target Lesions Week 121
- Corticosteroid With Lidocaine1
- Corticosteroid With Normal Saline1
Active Sponsors
- Vanderbilt University Medical Center1
- University of Arizona1
- Amgen1
Top Investigators
University of Arizona
Vanderbilt University Medical Center
Related Conditions
- Cutaneous Tumor1
- Acne1
- Epidermal Inclusion Cyst1
- Skin Cancer Squamous Cell1
- Skin Cancer1